Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Liabilities and Shareholders Equity (2016 - 2025)

Northwest Biotherapeutics' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $81.3 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $81.3 million for Q4 2025, up 204.14% from a year ago — trailing twelve months through Dec 2025 was $169.0 million (up 49.72% YoY), and the annual figure for FY2025 was $81.3 million, up 204.14%.
  • Liabilities and Shareholders Equity for Q4 2025 was $81.3 million at Northwest Biotherapeutics, up from $30.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $81.3 million in Q4 2025 to a low of $26.7 million in Q4 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $29.4 million (2024), against an average of $32.6 million.
  • The sharpest move saw Liabilities and Shareholders Equity surged 253.48% in 2021, then dropped 22.0% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $40.2 million in 2021, then fell by 22.0% to $31.3 million in 2022, then fell by 11.04% to $27.9 million in 2023, then fell by 4.08% to $26.7 million in 2024, then skyrocketed by 204.14% to $81.3 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $81.3 million, $30.6 million, and $29.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.